Edwards Lifesciences Corp, spun off from Baxter International in 2000, develops, manufactures, and markets medical devices and equipment for the treatment of advanced structural heart disease. The company is a market leader in core product categories such as surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. Approximately 60% of Edwards Lifesciences’ total revenue is generated outside the United States.